The Centre for Commercialization of Cancer Immunotherapy (C3i) will accelerate discovery, commercialization and access to innovative cancer immunotherapies for patients. Operating out of the Hôpital Maisonneuve-Rosemont installation of the Integrated University Center of East Montreal (CIUSS de l’Est-de-l’île-de-Montréal), the centre will offer an integrated structure for the development, translation and commercialization of these groundbreaking therapies. C3i will combine three interacting units that will provide patients with cutting edge biomarker and diagnostic tests, good manufacturing practices standards and rapid access to clinical trials and regulatory support to bring effective and affordable remedies more rapidly to Canadians and the world. This will strengthen Canada’s position as a leader in the emerging field of cancer immunotherapy.

Immunotherapy is a rapidly emerging practice that harnesses the power of the immune system to combat cancer. It could revolutionize cancer care by developing nontoxic, highly efficient and decisive cures that do not rely on chemotherapeutic agents, thus improving patients’ quality of life and reducing healthcare costs. These treatments could be used in 60% of advanced cancer patients by 2025. Canada needs greater capacity to translate these therapies into patient care, and to help Canadian companies compete in a potential $40 billion market.

Contact info:

  CCRM, a Canadian not-for-profit funded by the Government of Canada, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of academic researchers, leading companies, strategic investors and entrepreneurs, CCRM aims to accelerate the translation of scientific discovery into marketable products for patients with specialized teams funding, and infrastructure. CCRM sources and evaluates intellectual property from around the globe, offers various consulting services, conducts development projects with partners, and establishes new companies built around strategic bundles of intellectual property. CCRM has a 40,000 square foot space dedicated to advanced cell manufacturing that includes a fully resourced development facility used to both evaluate and advance technologies. CCRM is hosted by the University of Toronto and was launched in Toronto’s Discovery District on June 14, 2011.

Visit us at

 Contact Info: Spencer Hoover, Development Manager

Gold Sponsors

When science and passion connect, innovation happens. The oncology community shares a common mission: to transform the way patients live with cancer and related diseases. At Novartis Oncology, we are passionate about the discovery and development of innovative medicines. We seek to provide a broad range of new therapies as well as practical solutions to advance the care of patients.

With over 9000 Oncology employees worldwide operating in 85 countries, Novartis Oncology has a truly global reach. We have the advantage of extraordinarily talented and globally diverse employees who, through shared goals and different perspectives, are dedicated to transforming the lives of patients living with cancer around the world. We have developed eight new practice-changing medicines in the past decade, addressing unmet medical needs in patients worldwide. Our broad pipeline includes over 25 new molecular entities in development, targeting key molecular pathways in cancer biology.

Visit us at

  STEMCELL Technologies provides reagents to take cell therapy research from bench to bedside with T cell isolation, activation and expansion products. STEMCELL’s collaboration with GE Healthcare aims to give researchers the confidence of a path to the clinic with cGMP-grade T cell reagents. Learn more at

Bronze Sponsors

What we do

As a leading global medical technology and life sciences company, we provide a broad portfolio of products, solutions and services used in the diagnosis, treatment and monitoring of patients and in the development and manufacture of biopharmaceuticals.

We help improve outcomes for healthcare providers and for therapy innovators around the world. This means increased capacity, improved productivity and better patient outcomes.

We also aim to support our customers in the pursuit of precision health: health care that is integrated, highly personalized to each patient’s needs and that reduces waste and inefficiency.

We embrace a culture of respect, transparency, integrity and diversity.


  Kiadis Pharma’s allodepleted T-cell immunotherapy product candidate, given after a haploidentical hematopoietic stem cell transplantation (HSCT), is designed to reduce Graft versus Host Disease (GVHD) and relapse. Single dose Phase 2 data with lead product candidate ATIR101 has demonstrated substantial and clinically relevant improvements over historical observational cohort data for a similar HSCT without ATIR101, and also shows an improvement over the Post-Transplant Cyclophosphamide (PTCy), or Baltimore protocol, data reported in scientific literature. Based on the positive results from the Phase 2 trial, the Company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in April 2017, for approval of ATIR101 across the EU as an adjunctive treatment in HSCT for adult malignant disease. Kiadis Pharma submitted responses to the Day 120 List of Questions in March 2018 and received the Day 180 List of Questions in May 2018, CHMP opinion is expected H1 2019. Following potential EU approval, Kiadis Pharma intends to commercially launch ATIR101 in a first EU member state in the H2 2019. Kiadis Pharma is conducting a Phase 3 trial with ATIR101 across Europe and North America (head to head against the PTCy/Baltimore protocol). The first patient was enrolled in December 2017.

In September 2017 the U.S. Food and Drug Administration (FDA) granted ATIR101 the Regenerative Medicine Advanced Therapy (RMAT) designation. ATIR101 has been granted Orphan Drug Designations both in the U.S. and Europe.


Created in 2009, the TheCell Network has now more than one hundred full members. It strives to
facilitate phase I and II clinical studies in order to accelerate the availability of the technologies
developed in cell, tissue and gene therapy for the general population. The cell and tissue therapy
platforms of the universities throughout the province of Quebec and their partners are supported in
their clinical trial development.

TheCell is a thematic network supported by the Fonds de recherche du Québec–Santé provides leverage
and serves as catalyst for the utilization of the infrastructures and the training of highly qualified
personnel in the field of cell, tissue and gene therapy.

   BioCanRx was announced as a Network of Centres of Excellence on December 15, 2014, with a total of $60 million in funding and commitments from the NCE Program and more than 25 partners.


Its mandate it to be a global leader in the translation, manufacture and adoption of innovative cancer biotherapeutics for the benefit of all cancer patients by working in partnership with academia, industry, government, patients, charities and NGOs to identify, develop and de-risk promising cancer biotherapies.

BioCanRx is committed to excellent science in a field with great promise. Its focus is on translating this science into what we hope will be significantly better therapies for cancer patients. BioCanRx funds translational projects to accelerate the development of these therapies from the laboratory to the clinic. To that end, it has a goal of advancing four new cancer biotherapies into Canadian-led clinical trials by 2020.

Visit BioCanRx website